Howe & Rusling’s Regeneron Pharmaceuticals REGN Stock Holding History

Howe & Rusling’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$322K	Sell	416 -18	-4%	-$13.8K	0.02%	230
2025 Q4	$335K	Sell	434 -243	-36%	-$165K	0.02%	223
2025 Q3	$381K	Buy	677 +56	+9%	+$31.7K	0.03%	205
2025 Q2	$326K	Buy	621 +60	+11%	+$33.5K	0.02%	220
2025 Q1	$356K	Buy	561 +55	+11%	+$37.8K	0.03%	193
2024 Q4	$360K	Buy	506 +44	+10%	+$36.9K	0.03%	194
2024 Q3	$486K	Buy	462 +15	+3%	+$16.7K	0.04%	161
2024 Q2	$470K	Buy	447 +36	+9%	+$34.9K	0.04%	156
2024 Q1	$396K	Sell	411 -43	-9%	-$40.9K	0.04%	178
2023 Q4	$399K	Buy	454 +9	+2%	+$7.41K	0.04%	153
2023 Q3	$366K	Buy	445 +7	+2%	+$5.5K	0.04%	152
2023 Q2	$315K	Hold	438	–	–	0.04%	175
2023 Q1	$360K	Hold	438	–	–	0.04%	161
2022 Q4	$316K	Hold	438	–	–	0.04%	160
2022 Q3	$302K	Hold	438	–	–	0.04%	160
2022 Q2	$259K	Hold	438	–	–	0.03%	173
2022 Q1	$306K	Hold	438	–	–	0.04%	163
2021 Q4	$277K	Sell	438 -1	-0.2%	-$615	0.03%	176
2021 Q3	$266K	Buy	439 +1	+0.2%	+$621	0.03%	171
2021 Q2	$245K	Hold	438	–	–	0.03%	165
2021 Q1	$207K	Buy	438 +175	+67%	+$85.2K	0.03%	173
2020 Q4	$127K	Hold	263	–	–	0.02%	203
2020 Q3	$147K	Buy	263 +18	+7%	+$10.9K	0.03%	176
2020 Q2	$153K	Hold	245	–	–	0.03%	160
2020 Q1	$120K	Hold	245	–	–	0.03%	179
2019 Q4	$92K	Buy	+245	New	+$82.4K	0.02%	239
2018 Q4	–	Sell	-25	Closed	-$10K	–	883
2018 Q3	$10K	Buy	+25	New	+$9.52K	﹤0.01%	507
2018 Q2	–	Sell	-40	Closed	-$14K	–	911
2018 Q1	$14K	Buy	40 +35	+700%	+$12.2K	﹤0.01%	440
2017 Q4	$2K	Hold	5	–	–	﹤0.01%	728
2017 Q3	$2K	Sell	5 -20	-80%	-$9.52K	﹤0.01%	771
2017 Q2	$12K	Buy	25 +20	+400%	+$8.75K	﹤0.01%	449
2017 Q1	$2K	Hold	5	–	–	﹤0.01%	860
2016 Q4	$2K	Hold	5	–	–	﹤0.01%	884
2016 Q3	$2K	Hold	5	–	–	﹤0.01%	880
2016 Q2	$2K	Hold	5	–	–	﹤0.01%	839
2016 Q1	$2K	Hold	5	–	–	﹤0.01%	872
2015 Q4	$3K	Hold	5	–	–	﹤0.01%	748
2015 Q3	$2K	Hold	5	–	–	﹤0.01%	842
2015 Q2	$3K	Buy	+5	New	+$2.44K	﹤0.01%	790
2014 Q2	–	Sell	-111	Closed	-$33K	–	912
2014 Q1	$33K	Buy	+111	New	+$34.2K	0.01%	381
2013 Q4	–	Sell	-147	Closed	-$45K	–	870
2013 Q3	$45K	Hold	147	–	–	0.02%	342
2013 Q2	$33K	Buy	+147	New	+$34.2K	0.01%	407

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Howe & Rusling's REGN Position: Q1 2026 in Review

Howe & Rusling reduced its Regeneron Pharmaceuticals (REGN) stake by 4.1% in Q1 2026, selling an estimated $13.8K and leaving 416 shares worth $322K. The position accounts for 0.02% of the portfolio, ranked #230.

Howe & Rusling first reported a position in REGN in Q2 2013 and has held it in 42 quarters since. The position peaked at $486K in Q3 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Howe & Rusling held 416 shares of Regeneron Pharmaceuticals worth $322K as of Q1 2026.
Howe & Rusling sold 18 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $13.8K.
Regeneron Pharmaceuticals made up 0.02% of Howe & Rusling's portfolio in Q1 2026, its #230 holding.
Howe & Rusling first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 42 quarters since.
Howe & Rusling's Regeneron Pharmaceuticals position peaked at $486K in Q3 2024.
1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Howe & Rusling's 13F filing for Q1 2026, filed 28 Apr 2026.